Cargando…

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder

Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketami...

Descripción completa

Detalles Bibliográficos
Autores principales: Rong, Carola, Park, Caroline, Rosenblat, Joshua D., Subramaniapillai, Mehala, Zuckerman, Hannah, Fus, Dominika, Lee, Yena L., Pan, Zihang, Brietzke, Elisa, Mansur, Rodrigo B., Cha, Danielle S., Lui, Leanna M. W., McIntyre, Roger S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923813/
https://www.ncbi.nlm.nih.gov/pubmed/29673146
http://dx.doi.org/10.3390/ijerph15040771
_version_ 1783318430241259520
author Rong, Carola
Park, Caroline
Rosenblat, Joshua D.
Subramaniapillai, Mehala
Zuckerman, Hannah
Fus, Dominika
Lee, Yena L.
Pan, Zihang
Brietzke, Elisa
Mansur, Rodrigo B.
Cha, Danielle S.
Lui, Leanna M. W.
McIntyre, Roger S.
author_facet Rong, Carola
Park, Caroline
Rosenblat, Joshua D.
Subramaniapillai, Mehala
Zuckerman, Hannah
Fus, Dominika
Lee, Yena L.
Pan, Zihang
Brietzke, Elisa
Mansur, Rodrigo B.
Cha, Danielle S.
Lui, Leanna M. W.
McIntyre, Roger S.
author_sort Rong, Carola
collection PubMed
description Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to identify the pretreatment predictors of response to ketamine in TRD as part of MDD and BD. Method: Electronic search engines PubMed/MEDLINE, ClinicalTrials.gov, and Scopus were searched for relevant articles from inception to January 2018. The search term ketamine was cross-referenced with the terms depression, major depressive disorder, bipolar disorder, predictors, and response and/or remission. Results: Multiple baseline pretreatment predictors of response were identified, including clinical (i.e., Body Mass Index (BMI), history of suicide, family history of alcohol use disorder), peripheral biochemistry (i.e., adiponectin levels, vitamin B12 levels), polysomnography (abnormalities in delta sleep ratio), neurochemistry (i.e., glutamine/glutamate ratio), neuroimaging (i.e., anterior cingulate cortex activity), genetic variation (i.e., Val66Met BDNF allele), and cognitive functioning (i.e., processing speed). High BMI and a positive family history of alcohol use disorder were the most replicated predictors. Conclusions: A pheno-biotype of depression more, or less likely, to benefit with ketamine treatment is far from complete. Notwithstanding, metabolic-inflammatory alterations are emerging as possible pretreatment response predictors of depressive symptom improvement, most notably being cognitive impairment. Sophisticated data-driven computational methods that are iterative and agnostic are more likely to provide actionable baseline pretreatment predictive information.
format Online
Article
Text
id pubmed-5923813
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-59238132018-05-03 Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder Rong, Carola Park, Caroline Rosenblat, Joshua D. Subramaniapillai, Mehala Zuckerman, Hannah Fus, Dominika Lee, Yena L. Pan, Zihang Brietzke, Elisa Mansur, Rodrigo B. Cha, Danielle S. Lui, Leanna M. W. McIntyre, Roger S. Int J Environ Res Public Health Article Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority. In keeping with this view, the present narrative review aims to identify the pretreatment predictors of response to ketamine in TRD as part of MDD and BD. Method: Electronic search engines PubMed/MEDLINE, ClinicalTrials.gov, and Scopus were searched for relevant articles from inception to January 2018. The search term ketamine was cross-referenced with the terms depression, major depressive disorder, bipolar disorder, predictors, and response and/or remission. Results: Multiple baseline pretreatment predictors of response were identified, including clinical (i.e., Body Mass Index (BMI), history of suicide, family history of alcohol use disorder), peripheral biochemistry (i.e., adiponectin levels, vitamin B12 levels), polysomnography (abnormalities in delta sleep ratio), neurochemistry (i.e., glutamine/glutamate ratio), neuroimaging (i.e., anterior cingulate cortex activity), genetic variation (i.e., Val66Met BDNF allele), and cognitive functioning (i.e., processing speed). High BMI and a positive family history of alcohol use disorder were the most replicated predictors. Conclusions: A pheno-biotype of depression more, or less likely, to benefit with ketamine treatment is far from complete. Notwithstanding, metabolic-inflammatory alterations are emerging as possible pretreatment response predictors of depressive symptom improvement, most notably being cognitive impairment. Sophisticated data-driven computational methods that are iterative and agnostic are more likely to provide actionable baseline pretreatment predictive information. MDPI 2018-04-17 2018-04 /pmc/articles/PMC5923813/ /pubmed/29673146 http://dx.doi.org/10.3390/ijerph15040771 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rong, Carola
Park, Caroline
Rosenblat, Joshua D.
Subramaniapillai, Mehala
Zuckerman, Hannah
Fus, Dominika
Lee, Yena L.
Pan, Zihang
Brietzke, Elisa
Mansur, Rodrigo B.
Cha, Danielle S.
Lui, Leanna M. W.
McIntyre, Roger S.
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
title Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
title_full Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
title_fullStr Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
title_full_unstemmed Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
title_short Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
title_sort predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923813/
https://www.ncbi.nlm.nih.gov/pubmed/29673146
http://dx.doi.org/10.3390/ijerph15040771
work_keys_str_mv AT rongcarola predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT parkcaroline predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT rosenblatjoshuad predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT subramaniapillaimehala predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT zuckermanhannah predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT fusdominika predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT leeyenal predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT panzihang predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT brietzkeelisa predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT mansurrodrigob predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT chadanielles predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT luileannamw predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder
AT mcintyrerogers predictorsofresponsetoketamineintreatmentresistantmajordepressivedisorderandbipolardisorder